Review on development of potential inhibitors of SARS-CoV-2 main protease (MPro)
Abstract Background The etiological agent for the coronavirus illness outbreak in 2019–2020 is a novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19), whereas coronavirus disease pandemic of 2019 (COVID-19) has compelled the implementation of novel thera...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2022-06-01
|
| Series: | Future Journal of Pharmaceutical Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43094-022-00423-7 |
| _version_ | 1811230777022611456 |
|---|---|
| author | Soumya Gulab Katre Alpana Jagdish Asnani Kumar Pratyush Nilima Gangadhar Sakharkar Ashwini Gajanan Bhope Kanchan Tekram Sawarkar Vaibhav Santosh Nimbekar |
| author_facet | Soumya Gulab Katre Alpana Jagdish Asnani Kumar Pratyush Nilima Gangadhar Sakharkar Ashwini Gajanan Bhope Kanchan Tekram Sawarkar Vaibhav Santosh Nimbekar |
| author_sort | Soumya Gulab Katre |
| collection | DOAJ |
| description | Abstract Background The etiological agent for the coronavirus illness outbreak in 2019–2020 is a novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19), whereas coronavirus disease pandemic of 2019 (COVID-19) has compelled the implementation of novel therapeutic options. Main body of the abstract There are currently no targeted therapeutic medicines for this condition, and effective treatment options are quite restricted; however, new therapeutic candidates targeting the viral replication cycle are being investigated. The primary protease of the severe acute respiratory syndrome coronavirus 2 virus is a major target for therapeutic development (MPro). Severe acute respiratory syndrome coronavirus 2, severe acute respiratory syndrome coronavirus, and Middle East respiratory syndrome coronavirus (MERS-CoV) all seem to have a structurally conserved substrate-binding domain that can be used to develop novel protease inhibitors. Short conclusion With the recent publication of the X-ray crystal structure of the severe acute respiratory syndrome coronavirus 2 Mm, virtual and in vitro screening investigations to find MPro inhibitors are fast progressing. The focus of this review is on recent advancements in the quest for small-molecule inhibitors of the severe acute respiratory syndrome coronavirus 2 main protease. |
| first_indexed | 2024-04-12T10:33:45Z |
| format | Article |
| id | doaj.art-80d73cad47d04a65b446fefe24340bc9 |
| institution | Directory Open Access Journal |
| issn | 2314-7253 |
| language | English |
| last_indexed | 2024-04-12T10:33:45Z |
| publishDate | 2022-06-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Future Journal of Pharmaceutical Sciences |
| spelling | doaj.art-80d73cad47d04a65b446fefe24340bc92022-12-22T03:36:46ZengSpringerOpenFuture Journal of Pharmaceutical Sciences2314-72532022-06-01811910.1186/s43094-022-00423-7Review on development of potential inhibitors of SARS-CoV-2 main protease (MPro)Soumya Gulab Katre0Alpana Jagdish Asnani1Kumar Pratyush2Nilima Gangadhar Sakharkar3Ashwini Gajanan Bhope4Kanchan Tekram Sawarkar5Vaibhav Santosh Nimbekar6Department of Pharmaceutical Chemistry, Priyadarshini J L College of PharmacyDepartment of Pharmaceutical Chemistry, Priyadarshini J L College of PharmacyDepartment of Pharmaceutical Chemistry, Priyadarshini J L College of PharmacyDepartment of Pharmaceutical Chemistry, Priyadarshini J L College of PharmacyDepartment of Pharmaceutical Chemistry, Priyadarshini J L College of PharmacyDepartment of Pharmaceutical Chemistry, Priyadarshini J L College of PharmacyDepartment of Pharmaceutical Chemistry, Priyadarshini J L College of PharmacyAbstract Background The etiological agent for the coronavirus illness outbreak in 2019–2020 is a novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19), whereas coronavirus disease pandemic of 2019 (COVID-19) has compelled the implementation of novel therapeutic options. Main body of the abstract There are currently no targeted therapeutic medicines for this condition, and effective treatment options are quite restricted; however, new therapeutic candidates targeting the viral replication cycle are being investigated. The primary protease of the severe acute respiratory syndrome coronavirus 2 virus is a major target for therapeutic development (MPro). Severe acute respiratory syndrome coronavirus 2, severe acute respiratory syndrome coronavirus, and Middle East respiratory syndrome coronavirus (MERS-CoV) all seem to have a structurally conserved substrate-binding domain that can be used to develop novel protease inhibitors. Short conclusion With the recent publication of the X-ray crystal structure of the severe acute respiratory syndrome coronavirus 2 Mm, virtual and in vitro screening investigations to find MPro inhibitors are fast progressing. The focus of this review is on recent advancements in the quest for small-molecule inhibitors of the severe acute respiratory syndrome coronavirus 2 main protease.https://doi.org/10.1186/s43094-022-00423-7SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)MERS-CoV (Middle East respiratory syndrome coronavirus)Mpro inhibitor (main protease inhibitor)Virtual and in vitro screening |
| spellingShingle | Soumya Gulab Katre Alpana Jagdish Asnani Kumar Pratyush Nilima Gangadhar Sakharkar Ashwini Gajanan Bhope Kanchan Tekram Sawarkar Vaibhav Santosh Nimbekar Review on development of potential inhibitors of SARS-CoV-2 main protease (MPro) Future Journal of Pharmaceutical Sciences SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) MERS-CoV (Middle East respiratory syndrome coronavirus) Mpro inhibitor (main protease inhibitor) Virtual and in vitro screening |
| title | Review on development of potential inhibitors of SARS-CoV-2 main protease (MPro) |
| title_full | Review on development of potential inhibitors of SARS-CoV-2 main protease (MPro) |
| title_fullStr | Review on development of potential inhibitors of SARS-CoV-2 main protease (MPro) |
| title_full_unstemmed | Review on development of potential inhibitors of SARS-CoV-2 main protease (MPro) |
| title_short | Review on development of potential inhibitors of SARS-CoV-2 main protease (MPro) |
| title_sort | review on development of potential inhibitors of sars cov 2 main protease mpro |
| topic | SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) MERS-CoV (Middle East respiratory syndrome coronavirus) Mpro inhibitor (main protease inhibitor) Virtual and in vitro screening |
| url | https://doi.org/10.1186/s43094-022-00423-7 |
| work_keys_str_mv | AT soumyagulabkatre reviewondevelopmentofpotentialinhibitorsofsarscov2mainproteasempro AT alpanajagdishasnani reviewondevelopmentofpotentialinhibitorsofsarscov2mainproteasempro AT kumarpratyush reviewondevelopmentofpotentialinhibitorsofsarscov2mainproteasempro AT nilimagangadharsakharkar reviewondevelopmentofpotentialinhibitorsofsarscov2mainproteasempro AT ashwinigajananbhope reviewondevelopmentofpotentialinhibitorsofsarscov2mainproteasempro AT kanchantekramsawarkar reviewondevelopmentofpotentialinhibitorsofsarscov2mainproteasempro AT vaibhavsantoshnimbekar reviewondevelopmentofpotentialinhibitorsofsarscov2mainproteasempro |